Opioids are used to treat cases of acute and chronic pain that arise from a variety of causes, ranging from trauma to palliative care for advanced illness. Every year, 100 million people in the United States suffer from pain, 9-12 million of whom have chronic or persistent pain. Although opioid therapy is an important component […]
A 2014 review assessed MAT with methadone or buprenorphine-containing agents (Subutex®, Reckitt Benckiser Pharmaceuticals Inc.; Suboxone®, Indivior Inc.); dose-tapering strategies for methadone or Suboxone, with or without naltrexone (Revia®, Duramed Pharmaceuticals, Inc.; Vivitrol®, Alkermes, Inc.); use of naltrexone alone without prior stabilization on methadone or buprenorphine; and drug-free opioid withdrawal management. For questions or additional […]
Opioid use disorder has reached a critical level in the United States, driven by over-prescription and diversion of opioid painkillers, as well as the low cost and increased potency of heroin. The societal impact is substantial in terms of costs related to treatment, lost work productivity, criminal activity, and social welfare expenditure. The goals of […]
ICER assessed the comparative clinical effectiveness and economic value of supervised injection facilities (SIFs). ICER has reviewed other related topics, such as abuse-deterrent opioid formulations, medication-assisted treatment for opioid use disorder, and non-drug interventions for lower back pain. This review reinforced ICER’s commitment to provide an independent evaluation of the evidence around interventions that target […]
ICER assessed the comparative clinical effectiveness and economic value of digital health technologies (DHTs) for opioid use disorder. ICER has reviewed other related topics, such as abuse-deterrent opioid formulations, medication-assisted treatment for opioid use disorder, and non-drug interventions for lower back pain. The Midwest CEPAC determined current evidence is inadequate to demonstrate a net health […]
Recent Comments